Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v2-FR
Language English French
Date Updated 2020-03-05 2020-01-10
Drug Identification Number 02248416 02248416
Brand name FASTURTEC FASTURTEC
Common or Proper name Fasturtec Fasturtec
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients RASBURICASE RASBURICASE
Strength(s) 1.5MG 1.5MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 3 3
ATC code V03AF V03AF
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2020-02-03 2020-02-03
Actual start date
Estimated end date 2020-03-06 2020-02-28
Actual end date 2020-03-04
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments